




RealRate

PHARMACEUTICAL 2014

Northwest Biotherapeutics INC
Rank 219 of 234



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Northwest Biotherapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Northwest Biotherapeutics INC compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 3.3% points. The greatest weakness of Northwest Biotherapeutics INC is the variable Assets, reducing the Economic Capital Ratio by 86% points.

The company's Economic Capital Ratio, given in the ranking table, is 52%, being 190% points below the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	18,646
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	19,689
Liabilities, Non-Current	0
Other Assets	55
Other Compr. Net Income	0
Other Expenses	11,484
Other Liabilities	0
Other Net Income	1,156
Other Revenues	809
Property and Equipment	83
Research and Development	43,906
Selling, General and Administrative Expense	12,364

Output Variable	Value in 1000 USD
Assets	18,784
Liabilities	19,689
Expenses	67,754
Revenues	809
Stockholders Equity	-905
Net Income	-65,789
Comprehensive Net Income	-65,789
BaseVar	54,096
ECR before LimitedLiability	-352%
Economic Capital Ratio	52%